These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27677932)

  • 1. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological therapy of Parkinson's disease: current options and new avenues.
    Simola N; Pinna A; Fenu S
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease.
    Fowler AJ; Moussa CE
    CNS Drugs; 2018 Jan; 32(1):1-11. PubMed ID: 29492779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatments and compositions targeting α-synuclein: a patent review (2010-2016).
    Jęśko H; Lenkiewicz AM; Adamczyk A
    Expert Opin Ther Pat; 2017 Apr; 27(4):427-438. PubMed ID: 27841042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy.
    Ganguly U; Chakrabarti SS; Kaur U; Mukherjee A; Chakrabarti S
    Curr Neuropharmacol; 2018; 16(7):1086-1097. PubMed ID: 29189163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.
    Amer DA; Irvine GB; El-Agnaf OM
    Exp Brain Res; 2006 Aug; 173(2):223-33. PubMed ID: 16733698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response.
    Du Y; Wang F; Zou J; Le W; Dong Q; Wang Z; Shen F; Yu L; Li Y
    Neurobiol Aging; 2014 Oct; 35(10):2316-28. PubMed ID: 24866403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
    Rott R; Szargel R; Shani V; Bisharat S; Engelender S
    CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
    Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
    Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins.
    Cox D; Carver JA; Ecroyd H
    Biochim Biophys Acta; 2014 Sep; 1842(9):1830-43. PubMed ID: 24973551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
    Sass MB; Lorenz AN; Green RL; Coleman RA
    J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.